Recent Story Posts
Community
Reflecting on Treating the First Person Diagnosed with COVID-19 in the United States
Innovation
Four Questions with Anu Osinusi: Gilead’s Commitment to People Living with Viral Hepatitis
Community
Adonis Timone Aims to Create Change with Advocates for Youth
Recent Press Releases
-
June 28, 2021
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options -
June 28, 2021
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
For more information, contact us.
Phone:
1-800-GILEAD-5 (1-800-445-3235)
1-800-GILEAD-5 (1-800-445-3235)